Protein alteration of HepG2.2.15 cells induced by iron overload

Proteomics

Volumn 12, Issue 9, 2012, Pages 1378-1390

  Fang, Caiyun ^a   Zhao, Chao ^a   Liu, Xiaohui ^a   Yang, Pengyuan ^a   Lu, Haojie ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Cell biology; Hepatitis B virus; Hepatocellular carcinoma; Iron; ITRAQ

Indexed keywords

COLLAGEN TYPE 2; FERRITIN; FERROUS SULFATE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; HISTONE H4; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRON; MACROPHAGE MIGRATION INHIBITION FACTOR; NUP153 PROTEIN; PROTEIN 14 3 3 ALPHA; PROTEIN 14 3 3 BETA; UNCLASSIFIED DRUG; VIRUS PROTEIN;

APOPTOSIS; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN HEPG2; CONTROLLED STUDY; HEPATITIS B; IN VITRO STUDY; IRON OVERLOAD; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; STRESS; WESTERN BLOTTING;

ACTIVE TRANSPORT, CELL NUCLEUS; AMINO ACID SEQUENCE; BLOTTING, WESTERN; CHROMATOGRAPHY, LIQUID; FERROUS COMPOUNDS; HEP G2 CELLS; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HOST-PATHOGEN INTERACTIONS; HUMANS; IRON OVERLOAD; ISOTOPE LABELING; LIVER NEOPLASMS; MOLECULAR SEQUENCE DATA; NF-KAPPA B; NUCLEAR PORE COMPLEX PROTEINS; PROTEOME; PROTEOMICS; REPRODUCIBILITY OF RESULTS; TANDEM MASS SPECTROMETRY;

HEPATITIS B VIRUS;

EID: 84861139837     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201100335     Document Type: Article

References (33)

1. Sussman, H. H., Iron in cancer. Pathobiology 1992, 60, 2-9.
2. Felton, C., Lustbader, E. D., Merten, C., Blumberg, B. S., Serum iron levels and response to hepatitis B virus. Proc. Nat. Acad. Sci. USA 1979, 76, 2438-2441.
3. Blumberg, B. S., Lustbader, E. D., Whitford, P. L., Changes in serum iron levels due to infection with hepatitis B virus. Proc. Nat. Acad. Sci. USA 1981, 78, 3222-3224.
4. Bayraktar, Y., Koseoglu, T., Somner, C., Kayhan, B. et al., The use of deferoxamine infusions to enhance the response rate to interferon-alpha treatment of chronic viral hepatitis B. J. Viral Hepat. 1996, 3, 129-135.
5. Bayraktar, Y., Saglam, F., Temizer, A., Uzunalimodlu, B., et al., The effect of interferon and desferrioxamine on serum ferritin and hepatic iron concentrations in chronic hepatitis B. Hepatogastroenterology 1998, 45, 2322-2327.
6. Deugnier, Y., Iron and liver cancer. Alcohol 2003, 30, 145-150.
7. Kowdley, K. V., Iron, hemochromatosis, and hepatocellular carcinoma. Gastroenterology 2004, 127, S79-S86.
8. Petrak, J., Myslivcova, D., Man, P., Cmejla, R. et al., Proteomic analysis of iron overload in human hepatoma cells. Am. J. Physiol. Gastrointest. Liver Physiol. 2006, 290, G1059-G1066.
9. Tang, W. H., Shilov, I. V., Seymour, S. L., Nonlinear fitting method for determining local false discovery rates from decoy database searches. J. Proteome. Res. 2008, 9, 3661-3667.
10. Xiaochen Tian, Chao Zhao, Jun Ren, Zhangmei Ma, et al., Gene expression profiles of a hepatitis B small surface antigen secreting cell line reveal up-regulation of lymphoid enhancer-binding factor 1. J. Gen. Virol. 2007, 88, 2966-2976.
11. Sells, M. A., Chen, M. L., Acs, G., Production of hepatitis B virus particles in HepG2 cells transfected with cloned hepatitis B virus DNA. Proc. Nat. Acad. Sci. USA 1987, 84, 1005-1009.
12. Chouteau, P., Le Seyec, J., Saulier-Le Dréan, B., Cannie, I. et al., Inhibition of hepatitis B virus production associated with high levels of intracellular viral DNA intermediates in iron-depleted HepG2.2.15 cells. J. Hepatol. 2001, 1, 108-113.
13. Cheng, J., Imanishi, H., Morisaki, H., Liu, W. et al., Recombinant HBsAg inhibits LPS-induced COX-2 expression and IL-18 production by interfering with the NFkB pathway in a human monocytic cell line, THP-1. J Hepatol 2005, 43, 465-471.
14. Barandier, C., Tanguy, S., Pucheu, S., Boucher, F., et al., Effect of antioxidant trace elements on the response of cardiac tissue to oxidative stress. Ann. N. Y. Acad. Sci. 1999, 874, 138-155.
15. Yang, F., Yan, S., He, Y., Wang, F. et al., Expression of hepatitis B virus proteins in transgenic mice alters lipid metabolism and induces oxidative stress in the liver. J. Hepatol. 2008, 1, 12-19.
16. Sutnick, A. I., Blumberg, B. S., Lustbader, E. D., Elevated serum iron levels and persistent Australia antigen (HBsAg). Ann. Intern. Med. 1974, 81, 855-856.
17. Deugnier, Y., Battistelli, D., Jouanolle, H., Guyader, D. et al., Hepatitis B virus infection markers in genetic haemochromatosis. A study of 272 patients. J. Hepatol. 1991, 13, 286-290.
18. Martinelli, A. L., Filho, A. B., Franco, R. F., Tavella, M. H. et al., Liver iron deposits in hepatitis B patients: association with severity of liver disease but not with hemochromatosis gene mutations. J. Gastroenterol. Hepatol. 2004, 9, 1036-1041.
19. Reuther, G. W., Pendergast, A. M., The roles of 14-3-3 proteins in signal transduction. Vitam. Horm. 1996, 52, 149-175.
20. Cable, E. E., Connor, J. R., Isom, H. C., Accumulation of iron by primary rat hepatocytes in long-term culture: changes in nuclear shape mediated by non-transferrin-bound forms of iron. Am. J. Pathol. 1998, 3, 781-792.
21. Ferrali, M., Signorini, C., Sugherini, L., Pompella, A. et al., Release of free, redox-active iron in the liver and DNA oxidative damage following phenylhydrazine intoxication. Biochem. Pharmacol. 1997, 11, 1743-1751.
22. Neilands, J. B., Iron absorption and transport in microorganisms. Ann. Rev. Nutr. 1981, 1, 27-46.
23. Ryan, T. P., Aust, S. D., The role of iron in oxygen-mediated toxicities. Crit. Rev. Toxicol. 1992, 22, 119-141.
24. Valko, M., Leibfritz, D., Moncol, J., Cronin, M. T. et al., Free radicals and antioxidants in normal physiological functions and human disease. Int. J. Biochem. Cell. Biol. 2007, 39, 44-84.
25. Ishida, M., Nakagawara, G., Imamura, Y., Fukuda, M., Iron and copper deposition in chronic active hepatitis and liver cirrhosis: pathogenetic role in progressive liver cell damage. Eur. J. Histochem. 1995, 3, 221-236.
26. Ohkawara, T., Nishihira, J., Takeda, H., Asaka, M., et al., Pathophysiological roles of macrophage migration inhibitory factor in gastrointestinal, hepatic, and pancreatic disorders. J. Gastroenterol. 2005, 40, 117-122.
27. Lee, H., Rhee, H., Kang, H. J., Kim, H. S. et al., Macrophage migration inhibitory factor may be used as an early diagnostic marker in colorectal carcinomas. Am. J. Clin. Pathol. 2008, 5, 772-779.
28. Wilson, J. M., Coletta, P. L., Cuthbert, R. J., Scott, N. et al., Macrophage migration inhibitory factor promotes intestinal tumorigenesis. Gastroenterology 2005, 129, 1485-1503.
29. Mitchell, R. A., Mechanisms and effectors of MIF-dependent promotion of tumourigenesis. Cell Signal. 2004, 16, 13-19.
30. Britton, R. S., Ramm, G. A., Olynyk, J., Singh, R. et al., Pathophysiology of iron toxicity. Adv. Exp. Med. Biol. 1994, 356, 239-253.
31. Stoyanovsky, D. A., Cederbaum, A. I., Redox-cycling of iron ions triggers calcium release from liver microsomes. Free Radic. Biol. Med. 1998, 5, 745-753.
32. Moudry, P., Lukas, C., Macurek, L., Neumann, B. et al., Nucleoporin NUP153 guards genome integrity by promoting nuclear import of 53BP1. Cell Death Differ. 2012, 19, 798-807.
33. Elliott, M. H., Smith, D. S., Parker, C. E., Borchers, C., Current trends in quantitative proteomics. J. Mass Spectrom. 2009, 44, 1637-1660.